X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee
NCT01438918
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Subjects aged >= 40 years Diagnosed with knee OA (ACR definition of OA) Radiographic evidence of OA in the study knee
A diagnosis of any other rheumatic disease Current conditions in the study knee that would
confound efficacy Selected, traditional clinical safety and laboratory parameters
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Boston, Massachusetts
- Cleveland, Ohio
- Funabashi, Chiba
- Sakura, Chiba
- Chikushi-gun, Fukuoka
- Iizuka, Fukuoka
- Kurume, Fukuoka
- Yame, Fukuoka
- Chitose, Hokkaido
- Sapporo, Hokkaido
- Kamakura, Kanagawa
- Yokohama, Kanagawa
- Isahaya, Nagasaki
- Hirakata, Osaka
- Kanzaki-gun, Saga
- Karatsu, Saga
- Ogi-gun, Saga
- Itabashi-ku, Tokyo
- Setagaya-ku, Tokyo
- Shinjuku-Ku, Tokyo
- Taito-ku, Tokyo
- Yoyogi Shibuya-ku, Tokyo
- Saga,
- Tokyo,
- Bad Muender,
- Beckum,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Ostseebad Damp,
- Schwerin,
- Stade,
- Tostedt,
- Weener,
- Barcelona,
- Barcelona,
- Cadiz,
- Guadalajara,
- Madrid,
- Madrid,
- Madrid,
- Oviedo,
- Sevilla,
- Valencia,
- Chelmsly Wood, Birmingham
- Truro, Cornwall
- Chorley, Lancs
- Liverpool, Lancs
- Cannock, Mid Staffordshire
- Addlestone, Surrey
- Huddersfield,
- London,
- London,
- Manchester,
- Newcastle Upon Tyne,
- Wigan,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee | |||
Official Title ICMJE | A Long-term, Confirmatory, Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Investigate The Safety And Efficacy Of Orally Administered Sd-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee | |||
Brief Summary | The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS). The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Knee Osteoarthritis | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Withdrawn | |||
Actual Enrollment ICMJE | 0 | |||
Original Estimated Enrollment ICMJE | 1500 | |||
Estimated Study Completion Date ICMJE | December 2015 | |||
Estimated Primary Completion Date | December 2015 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Subjects aged >= 40 years Diagnosed with knee OA (ACR definition of OA) Radiographic evidence of OA in the study knee Exclusion Criteria: A diagnosis of any other rheumatic disease Current conditions in the study knee that would confound efficacy Selected, traditional clinical safety and laboratory parameters | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01438918 | |||
Other Study ID Numbers ICMJE | A6171017 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |